article · Xenobiotica

Genetic polymorphisms of ABCC2 and CBR3 can influence the efficacy and toxicity of doxorubicin therapy in Egyptian patients with non-Hodgkin lymphoma

2025Kafr el-Sheikh University

In plain language

The abstract on record is too brief for a reliable plain-language summary, so none has been generated.

Abstract

Polymorphisms in ABCC2 and CBR3 genes may contribute to individual variability in DOX-related toxicity and treatment response.

Research topics

Lung Cancer Treatments and Mutations
Acute Lymphoblastic Leukemia research
Lung Cancer Research Studies

Sustainable Development Goals

Zero Hunger

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

View on publisher site Record on OpenAlex

DOI: 10.1080/00498254.2025.2508814

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.

New to MARATTO™? Create a free account.